AIMS: Abnormal Involuntary Movement Scale
Abnormal Involuntary Movement Scale · Also known as: AIMS
The Abnormal Involuntary Movement Scale (AIMS) is the standard clinical rating scale for assessing tardive dyskinesia, a iatrogenic movement disorder resulting from chronic antipsychotic medication exposure. Developed by the National Institute of Mental Health in 1976, the 12-item scale systematically measures involuntary movements across facial, oral, limb, and trunk regions. The AIMS is mandatory screening tool for patients on long-term antipsychotic therapy and essential for monitoring antipsychotic-associated movement complications.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Baseline AIMS assessment recommended before initiating antipsychotic medication (within 1 week). Repeated AIMS every 6-12 months during antipsychotic treatment (FDA and American Psychiatric Association recommend ≥annually). Mandatory if patient reports involuntary movements or after antipsychotic dose increase (dyskinesia more common at higher cumulative doses). Essential before any long-term antipsychotic use in patients >40 years old or with tardive dyskinesia risk factors (older age, female sex, mood disorder, African American ethnicity). Serial AIMS guides medication adjustments: improvement suggests dose reduction/discontinuation feasibility; worsening suggests continued dose optimization or alternative agent consideration.
Strengths & limitations
- Gold-standard assessment tool for tardive dyskinesia; 50+ years of clinical validation and use globally.
- Simple binary observation-based rating (no patient cooperation required beyond performing movements); does not rely on subjective complaint or patient insight.
- Excellent inter-rater reliability (ICC 0.85-0.95) when raters trained via videotape standardization.
- Sensitive to dyskinesia presence and severity; discriminates absence from mild/moderate/severe dyskinesia effectively.
- Practical for routine clinical care; 10-15 minute administration fits into standard clinic visit.
- Enables early detection of dyskinesia before functional impairment develops, permitting preventive medication adjustments.
- Subjective rating of movement severity (mild vs moderate) subject to inter-rater variability despite training; videotape standardization helps but does not eliminate variability.
- Does not quantify movement frequency objectively; some raters may emphasize slow-frequency large-amplitude movements (more visible) while others detect rapid small-amplitude tremor. Standardization training critical.
- Dental status item (item 12) conflates with dyskinesia severity and may not be independent; some versions exclude this item.
- Baseline movement detection limited if patient intentionally suppresses movements or is unaware of mild dyskinesia; repeat assessments with explicit instruction to avoid voluntary suppression improve reliability.
- Does not differentiate etiology of movements (tardive dyskinesia vs Parkinson's tremor vs essential tremor vs cerebellar ataxia); clinical history and other neurological signs required.
- Most sensitive in orofacial region; limb dyskinesia may be underdetected if examiner does not observe during specific movement tasks (arm extension, finger tapping).
Frequently asked
What is the difference between tardive dyskinesia and akathisia?
Tardive dyskinesia is involuntary choreiform or dystonic movement (observable orofacial/limb dyskinesia) developing after chronic antipsychotic exposure. Akathisia is subjective feeling of inner restlessness and inability to sit still, with or without visible movement. AIMS measures dyskinesia (observable movements); akathisia requires separate assessment (patient subjective report or Akathisia Rating Scale). Patients may have both simultaneously. Akathisia may respond to beta-blockers; dyskinesia typically does not.
Can tardive dyskinesia improve or resolve?
Early tardive dyskinesia (<2 years onset) may partially resolve with dose reduction or antipsychotic discontinuation (30-50% improvement). Established tardive dyskinesia (>2 years) often persists despite medication changes but may improve slowly over years. Recent FDA-approved medications (valbenazine, tetrabenazine) treat established dyskinesia; approximately 40-50% patients achieve ≥25% AIMS reduction with these agents. Younger patients and shorter dyskinesia duration at treatment initiation predict better treatment response.
How often should AIMS be repeated?
FDA and professional guidelines recommend baseline AIMS (before/within 1 week of antipsychotic initiation) and repeat every 6-12 months during treatment. Higher-risk patients (age >40, prior dyskinesia, African American, female) warrant more frequent assessment (every 3-6 months). Immediately repeat if patient develops subjective awareness of involuntary movements or if antipsychotic dose increased. More frequent assessment (monthly) appropriate in clinical dyskinesia treatment trials.
What AIMS score constitutes 'tardive dyskinesia'?
There is no single cutoff score. Diagnostic criteria require: (a) current AIMS score >4 (≥2 items scored ≥2, OR ≥1 item scored ≥3) on any region. PLUS (b) ≥3 months antipsychotic exposure OR ≥1 month exposure and recent dose change. PLUS (c) dyskinesia not attributable to other medical conditions (hyperthyroidism, hypoglycemia, stroke). Baseline AIMS at pre-treatment establishes baseline; subsequent increase suggests antipsychotic-induced dyskinesia. Some patients score >4 at baseline (idiopathic movements); careful baseline assessment is essential.
Does AIMS assess other movement disorders?
AIMS specifically measures involuntary dyskinetic movements (orofacial and limb dyskinesia). It does NOT measure parkinsonism (bradykinesia, rigidity, resting tremor)—assessed separately via Extrapyramidal Symptom Rating Scale (ESRS) or Unified Parkinson's Disease Rating Scale (UPDRS). It does NOT measure akathisia (subjective restlessness)—assessed via subjective report or Akathisia Rating Scale. AIMS purely measures observable involuntary choreiform/athetoid movements.
Sources
- National Institute of Mental Health (1976). Abnormal Involuntary Movement Scale (AIMS). In: Rockland, L. H., Schooler, N. R., & Levine, J. (Eds.), Drug Treatment of Mental Disorders. New York: Raven Press. link ↗
How to cite this page
ScholarGate. (2026, June 3). Abnormal Involuntary Movement Scale. ScholarGate. https://scholargate.app/en/neurology/tardive-dyskinesia-rating-scale
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →